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Hypertension is the most common medical disorder encountered during pregnancy. Hypertensive disorders are one of the major
causesofpregnancy-relatedmaternaldeathsintheUnitedStates.Wewillpresentacomprehensiveupdateoftheliteraturepertinent
to hypertension in pregnancy. The paper begins by deﬁning and classifying hypertensive disorders in pregnancy. The normal
vascular and renal physiological changes which occur during pregnancy are detailed. We will summarize the intriguing aspects
of pathophysiology of preeclampsia, emphasizing on recent advances in this ﬁeld. The existing diagnostic tools and the tests
which have been proposed for screening preeclampsia are comprehensively described. We also highlight the short- and long-
term implications of preeclampsia. Finally, we review the current management guidelines, goals of treatment and describe the
potential risks and beneﬁts associated with various antihypertensive drug classes. Preeclampsia still remains an enigma, and the
present management focuses on monitoring and treatment of its manifestations. We are hopeful that this in depth critique will
stimulate the blossoming research in the ﬁeld and assist practitioners to identify women at risk and more eﬀectively treat aﬀected
individuals.
1.Introduction
Hypertension is the most common medical disorder of
pregnancy and is reported to complicate up to 1 in 10
gestations and aﬀects an estimated 240,000 women in the
United States every year [1]. Although physicians for millen-
nia have recognized preeclampsia, relatively little is known
about its pathogenesis and prevention. The primary concern
aboutelevatedbloodpressurerelatestothepotentialharmful
eﬀects on both mother and fetus. These potential adverse
eﬀects range in severity from trivial to life threatening.
2. Classiﬁcation of HypertensiveDisorders of
Pregnancy
The National High Blood Pressure Education Program of
the NHLBI classiﬁes hypertensive disorders of pregnancy
into following categories: gestational hypertension, chronic
hypertension,preeclampsia,andpreeclampsiasuperimposed
on preexisting hypertension [1]( T a b l e1).
Hypertension in pregnancy is deﬁned as a systolic of
140mmHg or greater or a diastolic of 90mmHg or greater.
Blood pressure should be taken in the upper arm with the
patient seated using an appropriately sized cuﬀ. The patient
should be at rest for at least several minutes. The blood
pressure should be conﬁrmed with another reading at least
at a twenty-minute interval or even on a separate occasion.
The diastolic reading is determined by the disappearance of
sound and not the change in sounds. Controversy remains
as to the blood pressure criteria used to deﬁne preeclampsia.
Someexpertsofthisspecializedareaofmedicinehaveargued
that a rapid rise in blood pressure of 30mmHg systolic
or 15mmHg diastolic should be suﬃcient to diagnose
preeclampsia. However, the current recommendations of the
2000 working group suggest that women who experienced
only this change are not yet preeclamptic but do warrant
close observation, especially if this ﬁnding is accompanied
by proteinuria and hyperuricemia [2].
2.1. Vascular Physiology of Normal Pregnancy. Dramatic
physiologicchangesoccurinsystemichemodynamicsduring
pregnancy. It is essential that these diﬀerences from the
nonpregnant state be appreciated when one attempts to
assess blood pressure during pregnancy. In uncomplicated2 Journal of Pregnancy
Table 1: Classiﬁcation of hypertension in pregnancy.
Chronic hypertension (i) increased BP before week 20 (or known to exist prior to pregnancy)
(ii) hypertension persistent for more than 12 weeks after pregnancy
Preeclampsia-eclampsia (i) de novo appearance of hypertension after mid-pregnancy
(ii) proteinuria at least 300mg/24hr
Preeclampsia superimposed upon existing
hypertension (i) new onset proteinuria
Gestational hypertension
(i) transient hypertension appearing after mid-pregnancy
(ii) conﬁrmed by return to normal BP postpartum
(iii) no proteinuria
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Figure 1: Relative changes in renal hemodynamics during normal
human pregnancy. Dramatic changes occur in systemic hemody-
namicsduringphysiologicpregnancy.Inuncomplicatedpregnancy,
mean arterial pressure drops, reaching its nadir between the 16th
and 20th weeks of gestation. After the 20th week, mean arterial
blood pressure slowly returns to close to pre-pregnancy levels
at about 40-week gestation. Changes in systemic blood pressure
are paralleled by a change in cardiac output which increases
dramatically. The apex is reached between the 16th and 20th weeks
of gestation. Plasma volume increases substantially as well but lags
behinds the increased cardiac output. MAP: mean arterial pressure.
CO: cardiac output.
pregnancy, mean arterial pressure drops, reaching its nadir
between the 16th and 20th weeks of gestation (Figure 1). The
decline in diastolic pressure is somewhat greater than that
in systolic pressure. The reduction is typically 8–10mmHg
or just less than a 10% decline from pre-pregnancy levels.
The fall in blood pressure begins with the luteal phase of
menstruation and progresses if conception follows. After
the 20th week, mean arterial blood pressure slowly returns
to prepregnancy levels at about 40-week gestation. The
circadian changes in blood pressure are maintained during
pregnancy as demonstrated by ambulatory blood pressure
monitoring.
Changes in systemic blood pressure are paralleled by
a change in cardiac output, which increases dramatically.
The apex is reached between the 16th and 20th weeks of
gestation, and at its apogee the increment is typically at
least 40% greater than the baseline. Both stroke volume
and heart rate increase to achieve this profound rise in the
quantity of blood pumped into the pulmonary and systemic
circulations[3].Thevolumeloadincreaseintheheartresults
in left ventricular hypertrophy that is commensurate with
the greater amount of cardiac work required to achieve
the increase in cardiac output [4]. The reduction in mean
arterial pressure is even more dramatic when placed in the
context of the change in cardiac output. Not only does the
cardiac output increase, but also plasma volume increases
substantially as well (Figure 1). This increased capacity of
the circulation with a diminished tone has led to description
of the vasculature as ﬂaccid during gestation. The reduced
smooth muscle tone is not limited to the vasculature, but
is shared, for example, with the smooth muscle of the
gastrointestinal and urinary tracts.
The circulating levels of the hormones that help regulate
blood volume, speciﬁcally all components of the renin-
angiotensin aldosterone system as well as catecholamines,
are paradoxically increased during gestation. The usual
physiologic stimuli for the release of these hormones are a
reduction in plasma volume or diminished renal perfusion.
Nonetheless, enhanced activity of the renin-angiotensin axis
is a hallmark of the volume-expanded state of gestation.
This has led to the description of pregnancy as a state of
“decreased eﬀective plasma volume.” Increases in both arte-
rial compliance and venous capacitance appear to underlie
this unique physiologic phenomenon [3], the understanding
of which remains enigmatic. As will be discussed subse-
quently, it is a reversal of this pattern that characterizes
the speciﬁc form of hypertension in pregnancy known as
preeclampsia.
The alterations in vascular reactivity are not limited
to the responses to endogenous hormones. The vaso-
constrictive eﬀect of infused pressor compounds is also
substantiallydiminished.Duringgestation,pregnantwomen
were demonstrated to be resistant to the pressor eﬀect of
angiotensin II and norepinephrine more than 40 years ago
[5, 6]. Subsequently, Gant and associates demonstrated a
sequential increment in the resistance to angiotensin II as
pregnancy progressed, which peaked between 24–30 weeks
of gestation [7] (Figure 2).Journal of Pregnancy 3
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Figure 2: The amount of angiotensin required to raise blood
pressure by 20mm Hg. This ﬁgure demonstrates two important
ﬁndings obtained from serial observations in primiparas. Women
undergoing physiologic pregnancy () become resistant to the
pressor eﬀect of infused angiotensin II by 14 weeks of gestation.
They require signiﬁcantly higher dose of angiotensin II to increase
blood pressure by 20mm of Hg. In contrast, women destined to
develop preeclampsia () regain their sensitivity to angiotensin II
between 22–26 weeks of gestation, well before any other clinical
manifestations of preeclampsia are appreciated [7].
2.2. The Kidney in Normal Pregnancy. Healthy pregnant
women show marked glomerular hyperﬁltration. The rapid
developing rise in renal blood ﬂow and glomerular ﬁltration
rate were documented in careful studies undertaken in
humans [8]. GFR begins to increase in the ﬁrst trimester of
pregnancy and peaks in second half of pregnancy, wherein
it is increased above normal, nongravid levels by 40–60%.
Davison and his associates found that these improvements
in renal hemodynamics occurred even prior to the changes
in cardiac output and plasma volume (Figure 3). This
suggests that the mechanisms underlying these profound
physiologic alterations may diﬀer from each other or at least
are not interdependent. There is no other instance in biology
where such a sustained improvement of function occurs.
The magnitude of the change has led many investigators to
attempt to deﬁne the mechanism that underlies it so that it
might be employed to treat other human conditions. Thus
far no deﬁnitive explanation has been proven. If pregnancy
remains uncomplicated, pregnant patients with underlying
renal disease usually experience an improvement in function
that is proportional to their baseline level. The reason for the
physiologic change presumably is teleological and designed
to accommodate the additional waste products consequent
totheenlarginguterus,placenta,andfetus.Althoughittends
to tail oﬀ toward the end of gestation, a substantive increase
in both glomerular ﬁltration rate and renal plasma ﬂow is
sustained throughout the pregnancy. The enhanced renal
function is accompanied by a reciprocal reduction in blood
urea nitrogen (BUN) and serum creatinine tests commonly
employed to estimate glomerular ﬁltration rate. Low blood
levels of these nitrogenous waste products are hallmarks of
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Figure 3: Changes in renal function during pregnancy. Kidney
function also dramatically increases during pregnancy. The rapid
developing rise in renal blood ﬂow and glomerular ﬁltration rate
were documented in careful studies undertaken in humans. These
increments average between 40 and 50%. Dr. Davison and his
associates found that these improvements in renal hemodynamics
occurred even prior to the changes in cardiac output and plasma
volume. GFR: glomerular ﬁltration rate. ERPF: eﬀective renal
plasma ﬂow [8].
Table 2: Laboratory tests of renal function during pregnancy.
Nonpregnant Pregnant
BUN 13 ±38 .17 ±1.5
Creatinine 0.67 ±0.14 0.46 ±0.13
Creatinine clearance 80–120 125
Serum uric acid Greater than 4 Less than 4
Urinalysis Normal Normal
physiologic pregnancy (Table 2). It is critical to be cognizant
of these diﬀerences from the normal nonpregnant values
since subtle deviations from the pregnancy levels might
presage the diagnosis of preeclampsia.
Throughout pregnancy the average women will retain
about 1000mEq of sodium as she experiences the fairly
steadyincreaseinextracellularandplasmavolume.Nonethe-
less women experiencing physiologic pregnancy will respond
appropriately to sodium restriction or sodium infusion [3].
2.3. Volume and Hemodynamic Alterations in Preeclampsia.
It is diﬃcult to study totally untreated preeclampsia, and
often preeclampsia is diagnosed in patients with underlying
chronic medical conditions. Data generated from treated
preeclamptic patients or those patients with preexisting
renal disease, diabetes, or hypertension might not accurately
reﬂect those of the uncomplicated preeclamptic patient.4 Journal of Pregnancy
These concerns aside, the available data suggests that the sys-
temic hemodynamic preeclamptics vary substantially from
those of women with uncomplicated pregnancy.
VisserandWallenburgundertookdetailedhemodynamic
assessments of untreated primiparous preeclamptics. Using
Swan-Ganz catheters, they consistently found cardiac out-
puts and intravascular volumes lower and systemic vascular
resistance and cardiac afterload higher in these carefully
selected group of women with pregnancy-induced hyperten-
sion as compared to normal control pregnant subjects [3].
If one focuses on the properties of the arterial system
in preeclampsia using impedance techniques, compliance of
the large conduit arteries is reduced. This suggests that the
reservoir properties of the arterial system are compromised.
The left ventricle muscle mass and cardiac wall diastolic
pressureinlategestationissimilarbetweenpreeclampticand
controlled subjects. Limited data suggests, however, that left
ventricular contractility in preeclamptics is inappropriately
low given the high afterload [3].
Somechangesinthesystemichemodynamicsofpregnant
women destined to become preeclamptic may develop prior
to overt clinical manifestations of the disease. Ambulatory
blood pressure readings suggest that a reduction or oblit-
eration in the usual decrease in nocturnal blood pressure
may be present in many patients who eventually become
preeclamptic. Such changes usually manifest at 18 to 26
weeks of gestation. The resistance to pressor substances
appears to be altered well before the systemic hypertension
and proteinuria are noted. Figure 2 shows that the sensitivity
tothepressoreﬀectofinfusedangiotensinchangesinwomen
destined to become preeclamptic. These individuals exhibit
sensitivity similar to that seen in nonpregnant women well
before they clinically manifest preeclampsia. In contrast,
claims that high cardiac output necessarily precedes the
development of preeclampsia appear to be based on an
insuﬃcient database [3].
Renin levels actually decrease in preeclamptic patients,
but remain well above those of nonpregnant individuals.
Similar changes are also seen in the circulating levels of
aldosterone and angiotensin II. Maintaining relatively high
levels of these hormones may be critically important because
mostoftenpreeclampticpatientshavearelativelydiminished
plasma volume.
2.4. Renal Alterations in Preeclampsia. The dramatic
improvement in renal function experienced by women
undergoing a physiologic pregnancy is abrogated in women
who develop preeclampsia. The GFR and renal blood ﬂow
decline. The severity of the reduction is quite variable
and correlates with the overall severity of the illness. If
proteinuria develops, as is most common, and a kidney
biopsy were to be undertaken, it would typically show
glomerular endotheliosis. This lesion, although not limited
to pregnancy, is characteristic in preeclamptic women. This
endothelialabnormalityisquiteconsistentwiththenotionof
endothelial injury playing a key role in the pathophysiology
of this systemic condition with the kidney not being spared.
These hemodynamic and endothelial changes also appear to
make the kidneys more vulnerable for the development of
acute renal failure (acute tubular necrosis) and uncommonly
a particular form of acute, often irreversible renal failure
known as renal cortical necrosis. Cortical necrosis is seen
almost exclusively in severe preeclamptics and rarely occurs
in settings outside of pregnancy [9].
2.5. Pathophysiology of Preeclampsia. The pathophysiology
of de novo hypertension and proteinuria in pregnancy
known as preeclampsia remains largely undiscovered. More
than 30 years ago Dr. Leon Chesley, a champion in the
ﬁeld of hypertension in pregnancy divided the most likely
causative factor into four major categories: dietary, renal,
immunologic,andplacental[10].Subsequently,theevidence
that poor diet or preexisting renal abnormalities underlie the
majority of episodes of preeclampsia has not been sustained.
The role of immunologically mediated vascular injury, as the
initiating cause remains plausible and will be explored.
Delivery of the placenta usually initiates the resolution of
the acute clinical symptoms of preeclampsia, suggesting that
the placenta plays a central role in preeclampsia pathogen-
esis. During normal pregnancy, the placenta undergoes dra-
maticvascularizationtoenablecirculationbetweenfetusand
mother. Placental vascularization involves vasculogenesis,
angiogenesis, and pseudovasculogenesis or maternal spiral
artery remodeling. These processes require a delicate balance
of proangiogenic and antiangiogenic factors. The imbalance
of proangiogenic and antiangiogenic factors in preeclampsia
is thought to trigger abnormal placental vascularization and
disease onset.
Underlying genetic explanations for the overproduction
of anti-angiogenic factors in preeclampsia are still being
proposed [11].
2.6. The Role of Uteroplacental Ischemia. Altered uteropla-
cental blood ﬂow has long been the focus of the patho-
physiologyofpreeclampsia.Cliniciansandresearchscientists
have garnered a wealth of data to support the hypothesis
that a reduction in uterine blood ﬂow is the overriding
factorintheetiopathogenesisofthiscondition(Table3).The
placentae of women with preeclampsia are uniformly abnor-
mal. The primary pathology appears to be at the maternal-
fetal interface and is characterized by poor trophoblastic
invasion of the uterus. The endovascular invasion of the
spiral arteries is incomplete. Speciﬁcally, the failure of the
cytotrophoblasts to penetrate deep and cause a “widening
of the pathway” appears to explain the relative reduction
in uteroplacental blood ﬂow. Additional pathologic ﬁndings
include placental infarcts. It is not surprising; consequently,
that intrauterine growth retardation is frequently associated
with preeclampsia. Virtually all clinical settings that favor the
development of preeclampsia also favor the possibility that
growth of the intrauterine contents outstrips the capacity to
commensurately improve blood supply.
Finally,thereisawealthofdataderivedfromexperiments
in various pregnant mammals spanning the spectrum from
rats to primates supporting this hypothesis. When subjected
to reduced uteroplacental blood ﬂow, these animals developJournal of Pregnancy 5
Table 3: Observations supporting uteroplacental ischemia as a key factor in preeclampsia.
(i) predominantly occurs in primagravidas with immature uterine vasculature
(ii) consistent abnormalities of the placentae and uteroplacental vascular interface
(iii) increased risk with more fetuses and placentas (twins)
(iv) disease occurs late in gestation
(v) labor aggravates
(vi) high incidence with large, rapidly growing hydatidiform moles
(vii) increase incidence in patients with underlying vascular disease (diabetes, hypertension and lupus (SLE))
(viii) ﬁndings in animals subjected to uteroplacental ischemia mimic those of preeclampsia
ﬁndings that mimic those seen in preeclamptic women. Sus-
tained hypertension, proteinuria, and glomerular endothe-
liosis, the renal lesion that characterizes preeclampsia, have
all been reported in these laboratory animals following
uterine constriction of blood ﬂow [12].
2.7. Maternal Endothelial Dysfunction. Although preeclamp-
sia appears to originate in the placenta, the tissue aﬀected
most is the maternal endothelium. The clinical mani-
festations of preeclampsia reﬂect widespread endothelial
dysfunction, with vasoconstriction and end organ ischemia.
Systemic hypertension, renal, hepatic, and cerebral vascular
pathology are hallmarks of severe preeclampsia. Taylor,
Davidge and Roberts explore in great depth the evidence
placing endothelial dysfunction as the focal point of the
disease[13].Theypointoutthatendothelial“activation”and
dysfunction are reﬂected in the inappropriate vasoconstric-
tion and its propensity toward a hypercoagulable state and
thewidespreadmicrovascularthrombi,mostnotablythatare
seennearlyuniformlyintheplacentaofpreeclamptics.These
investigators suggest that endothelial dysfunction may be
manifested by the altered synthesis and release of endothelial
cell products. Among the various compounds, which act
on the endothelium, are the prostanoids and nitric oxide.
Nitric oxide synthesis is increased in women undergoing
physiologic pregnancy, whereas analysis of tissue and urine
samples strongly suggest that nitric oxide production is
impaired in preeclamptic women. In laboratory animals
nitric oxide synthase inhibition can produce a condition,
whichbearsmanysimilaritiestopreeclampsia[12].Likewise,
there appears to be a role for possible imbalance between
vasodilating and vasoconstricting prostaglandins. Synthesis
of the vasorelaxant prostacyclin increases in physiologic
pregnancies, whereas more of the vasoconstrictor throm-
boxane is produced in women whose pregnancies are com-
plicated by high blood pressure and proteinuria. Whether
these particular compounds play a primary role or are only
a part of the progression of the pathophysiology is unclear.
A treatment strategy, nonetheless, was devised using low-
dose aspirin to attempt to conﬁrm the relationship between
thromboxane and vasodilating prostaglandins, since low-
dose aspirin may selectively inhibit thromboxane synthesis.
The results of studies on a large number of primiparous
women who were not at high risk to develop preeclampsia
failedtosupportabeneﬁtfromthisstrategy.Someadvocates,
however, still hold to the notion that selective treatment of
women who are at extremely high risk because of preexisting
hypertension or renal disease for example, may be of beneﬁt.
2.8. Antiangiogenic Factors in Preeclampsia. There is a pub-
lished body of work that has grown almost logarithmically
since 2003 suggesting that circulating angiogenic factors play
a key role in the pathogenesis of preeclampsia. Increased
expression of soluble fms-like tyrosine kinase (sFlt1),
together with decreased placental growth factor (PGF) and
vascular endothelial growth factor (VEGF) signaling, were
the ﬁrst abnormalities described [14].
2.8.1. sFlt1: A Circulating Antagonist to VEGF and PGF.
SeveralinvestigatorsspearheadedbyKarumanchihaveseized
on the ﬁnding that pregnant women may produce a solu-
ble variant of vascular endothelial growth factor receptor.
This kinase has been designated sFlt1. sFlt1 consists of
the extracellular ligand-binding domain of Flt1, but lacks
the transmembrane and intracellular signaling domain.
Hence, it is secreted into the circulation where it binds
and antagonizes both vascular endothelial growth factor
(VEGF) and placenta growth factor (PGF) [15]. Both are
potent stimuli for the vascular expansion essential to the
development of the uteroplacental unit and act via their
eﬀects on endothelial cells [16]. Even more recent clinical
evidence has been gathered that supports the notion that
both circulating and placental levels of this soluble receptor
blocker are higher in women with preeclampsia than in
women with uncomplicated pregnancy. These hypertensive
women also have been demonstrated to have lower levels
of PGF and VEGF. Circulating levels of sFlt1 and PGF are
altered several weeks before the onset of clinical disease
and are correlated with severity of the disease [17, 18].
sFlt1 levels normalize several days after delivery, coinciding
with improvement in proteinuria and hypertension. Support
for the key role of this kinase in the pathophysiology of
preeclampsia has been garnered from studies undertaken
in a baboon model of hypertension in pregnancy induced
by uteroplacental ischemia [19]. In these primates with
restricted uterine arteries, a temporal link was observed
betweentheonsetofhypertensionandrenaldysfunctionand
theincreaselevelofthekinase.Thisriseinthekinasewasalso
correlated with the blunted eﬀectiveness of PGF and VEGF.
Based on the ﬁndings in preeclamptic women, assays that
measure s-Flt, PGF, and VEGF have been touted as potential6 Journal of Pregnancy
tools to diﬀerentiate preeclampsia from other categories of
hypertension in pregnancy.
More recent studies have identiﬁed a second sFlt1
splice form expressed in cytotrophoblasts, which diﬀers
in its c-terminus and also appears to be upregulated in
preeclampsia [20]. The biologic signiﬁcance of the diﬀerent
sFlt1 variants with regards to anti-angiogenic activity and
their role in the pathogenesis of preeclampsia is a subject
of ongoing study. Selectively removing soluble FMS-like
tyrosine kinase, using an extracorporeal adsorption tech-
nique, reduced proteinuria, stabilized blood pressure, and
permitted prolongation of pregnancy in a small group of
women with preeclampsia very early in pregnancy. This
observation supports the notion that this protein kinase has
a role in the pathophysiology of preeclampsia [21].
2.8.2. Soluble Endoglin: A Circulating Antagonist to Trans-
forming Growth Factor-B. Proponents of the vascular
endothelial growth factor-receptor antagonist hypothesis or
so-called anti-angiogenic theory recognize that blocking
the action of these growth factors alone was insuﬃcient
to explain all the clinical manifestations seen in severe
eclampsia. Another factor, soluble endoglin (sEng), has
now been also found to be upregulated in preeclampsia
in a pattern similar to sFlt1. sEng is a truncated form of
endoglin (CD 105), a cell surface receptor for transforming
growth factor B (TGF-B), which binds and antagonizes
TGF-B [22]. This compound not only potentiates the anti-
angiogenic actions of s-Flt-1 kinase, but ultimately results
in the decreased production of nitric oxide. This type
of endothelial abnormality would be requisite to account
for the disseminated intravascular coagulation and the
other hematologic components seen in patients with severe
preeclampsia.
As with sFlt1, circulating sEng levels are increased weeks
before preeclampsia onset, and increased sEng levels are
observedinthereduceduterineperfusionpressureratmodel
of preeclampsia [23]. Cultured placental trophoblasts from
women with preeclampsia show increased sEng and sFlt1
expression, both at normoxic conditions and in response
to hypoxia, as compared with normal placental trophoblasts
[24].
Endoglin excess has now been incorporated into the
anti-angiogenic theory. Collectively, this is an appealing
hypothesis. Skeptics could say, however, we may not as yet
have reached the root cause level.
3.RelaxininPregnancy
Relaxin, a peptide hormone secreted by the corpus luteum,
circulates during pregnancy in human beings, nonhuman
primates, rats,and mice [25].The hormone alsois detectable
in the circulation during the luteal phase of the menstrual
cycle in both women and nonhuman primates [25]. Tra-
ditionally, relaxin has been investigated in the context of
the reproductive tract; however, it was suggested by Hisaw
et al. that relaxin has a vasodilatory role [26, 27], this was
further shown in subsequent studies by St-Louis and Massi-
cotte [28]. Relaxin administration to nonpregnant rats was
shown to mimic the vasodilatory phenomenon of pregnancy
[29]. Furthermore, immunoneutralization of relaxin or its
elimination from the circulation during midterm pregnancy
in rats prevents maternal systemic and renal vasodilation,
and the increase in global arterial compliance [30]. Evidence
suggests that the vasodilatory responses of relaxin are medi-
ated by its major receptor, the relaxin/insulin-like family
peptide 1 receptor, RFXP 1 [31], that is largely expressed in
vascular smooth muscle [32]. The possibility that angiogenic
growth factors may be secreted by the vascular smooth
muscle upon RFXP1 activation is being entertained [32].
Jeyabalan et al. reported an association of low ﬁrst trimester
relaxin concentrations with increased risk of developing
preeclampsia [33]. This study raised the possibility that
these women may experience defective decidualization and
trophoblast invasion or fail to adequately vasodilate in early
pregnancy owing to low levels of circulating relaxin, thereby
predisposing them to develop preeclampsia.
4.ReninAngiotensinSignalinginPreeclampsia
There is an increase in almost all the components of renin-
angiotensin system during an uncomplicated pregnancy, but
renin activity, angiotensin II, and aldosterone decrease in
preeclampsia for reasons that are unclear. Numerous studies
report the presence of angiotensin II type 1 receptor ago-
nistic antibody (AT1-AA) found circulating in preeclamptic
women [34, 35]. Many recent studies have shown that
by activating AT1 receptors on a variety of cell types,
these autoantibodies could increase certain factors (includ-
ing sFlt1, sEng, Plasminogen activator inhibitor-1, reactive
oxygen species, tissue factor, and NADPH oxidase) that lead
to preeclamptic pathophysiology such as endothelial cell
dysfunction and vascular damage [36, 37]. Granger et al.
isolated AT-AA1 from the rats manipulated by reduction
in uterine perfusion pressure. These rats also demonstrated
development of hypertension, proteinuria, increased sFlt1,
endothelin production, and endothelial dysfunction [38].
5.TheRoleofAlterationsoftheImmuneSystem
Over the last 30 years, signiﬁcant progress has been made
in understanding the role of immune mechanisms in the
development of preeclampsia. It remains unexplained why
primiparous women are more susceptible to this condition
and also why the high preeclampsia attack rate (5–7%) noted
in primiparous is unchanged in women who are having
a ﬁrst pregnancy with a second partner. This has fostered
the suspicion that the immunologic diﬀerence between the
partners,embeddedinthefetustriggersanimmuneresponse
in pregnant women. Redman et al. have postulated that
preeclampsia is the continuum of the immune-mediated
inﬂammatory changes seen in normal pregnancy. Most
investigators believe that endothelial injury, perhaps caused
by cytokine release induced by inﬂammation is a basicJournal of Pregnancy 7
mechanism underlying the pathogenesis of preeclampsia
[39].
It has also been postulated that immune accommodation
to the fetus needs to be learned, and this adaptation may
be relatively defective in the ﬁrst pregnancy leading to the
higher preeclampsia attack rate which declines in but less
so in subsequent pregnancies. Such conditioning might be
acquired from previous pregnancy, abortion, and exposure
to paternal semen and seminal plasma. Maternal exposure
to fetoplacental tissues varies with gestational age, and two
interfaces have been described. Interface 1, which is predom-
inant in the ﬁrst half of pregnancy, exists between maternal
immune cells and invasive, extravillous HLA expressing tro-
phoblastsindecidua.Interface2,whichpredominatesduring
thesecondhalfofpregnancy,comprisessyncytiotrophoblasts
that are in contact with maternal blood-borne immune cells.
SyncytiotrophoblastsareHLAnegative,andthusthepaternal
alloantigens are only expressed at interface 1, which is most
active in ﬁrst half of pregnancy [39].
It is tempting to suggest that those women who respond
vigorously to these foreign antigens are more susceptible
to develop endothelial injury that precedes preeclampsia.
Women indeed often develop persistent antibodies to the
fetal HLA antigens of paternal origin. The presence of these
antibodies substantially increases the rate of graft rejection
posttransplant.Itisofnotethattheendotheliumisthemajor
attack site of antibody-mediated rejection that develops not
uncommonly in this setting.
6. Role of GeneticsinPreeclampsia
Although the risk factors for preeclampsia are both genetic
and environmental, the presence of preeclampsia in ﬁrst
degree relatives increases a woman’s risk of preeclampsia by
2t o4f o l d[ 40, 41]. Genetic factors may play an important
role in the angiogenic imbalance found in patients with
preeclampsia. Recently, several polymorphisms in sFlt1 and
VEGF have been associated with severity of preeclampsia
[42]. Although circulating PGF, sFlt1, and sEng levels have
been shown to be important markers of preeclampsia, no
causal mutations in these genes associated with preeclampsia
have been identiﬁed so far [43]. However, women with
trisomy 13 fetuses have a higher incidence of preeclampsia
[44], suggesting that gene dosage or copy number variation
maycontributetothedevelopmentofpreeclampsia.Notably,
the Flt1 gene is located on chromosome 13.
There is some evidence to suggest that in addition to
maternal genotype, paternal (or fetal) genotype may also
contribute to risk of preeclampsia. The risk of fathering
a preeclamptic pregnancy is increased among males who
fathered a preeclamptic pregnancy with a diﬀerent partner
[45]. Also, men who are born from a pregnancy complicated
by preeclampsia are at a higher risk of fathering a preeclamp-
tic pregnancy [46].
7.DiagnosisofPreeclampsia
The diagnosis of preeclampsia is largely based upon meeting
the characteristic clinical features outlined above which
deﬁne preeclampsia. In this section, we explore various
tools proposed to predict the development and/or accurately
diagnose preeclampsia.
7.1. Clinical Assessment. The hallmark features in
preeclampsia include developing systolic blood pressure
(SBP) ≥140, or diastolic blood pressure (DBP) ≥90, and
proteinuria of 0.3 grams or greater in a 24-hour urine
specimen after 20 weeks of gestation in a woman who was
previously normotensive. Hypertension is generally the
earliest physical abnormality seen in preeclampsia and is the
most important clinical clue to the presence of the disease.
Since SBP and DBP readings are an essential part of the
diagnosis of preeclampsia, ensuring that the optimal and
appropriate ways are employed to measure BP cannot be
overemphasized.
Using diﬀerent indices of BP to predict preeclampsia has
beencomprehensivelyevaluatedinameta-analysispublished
byCnossenetal.[47].Thismeta-analysisincluded34studies
and evaluated using SBP, DBP, mean arterial pressure, and
theincreaseovertimeinBP.Thedatafromthismeta-analysis
supports the conclusion that BP measurements in the ﬁrst
and second trimesters have only a modest ability to predict
preeclampsia [47].
7.2. Laboratory Tests
(1) Proteinuria. Although proteinuria is generally consid-
ered an essential characteristic of preeclampsia, preeclamp-
sia should be suspected in any pregnant woman with
hypertension and characteristic signs or symptoms, even if
proteinuria is absent. Twenty percent of women who develop
eclampsia have no proteinuria and 10 percent of women
with other clinical and/or histological manifestations of
preeclampsiahavenoproteinuria[48].Womenwithprotein-
uria detected by urine dipstick should undergo quantitative
measurement of protein excretion. Use of the urine protein:
creatinine (P:C) ratio to estimate 24h protein excretion for
the diagnosis of preeclampsia has been controversial. The
P:C ratio has been compared with 24h urine collection
in pregnant women with discordant conclusions. Though
the earlier studies reﬂected that urine protein: creatinine
ratios did not correlate with 24-hour urine protein excretion
during gestation [48], the more recent literature suggests
a signiﬁcant correlation between these tests [49]. A meta-
analysis involving 974 pregnant women from 10 studies
showed a pooled sensitivity of 90% and speciﬁcity of 78%
using P:C ratio cutoﬀs between 0.19 and 0.25, as com-
pared with “gold standard” of 24h urine protein excretion
(>300mg/day) [50]. Most misclassiﬁcations tended to occur
in women with borderline proteinuria (250 to 400mg/day)
[51]. Hence it is reasonable to use the urine P:C ratio for the
diagnosis of preeclampsia, with 24h collection undertaken
when the results are equivocal. Microalbuminuria and8 Journal of Pregnancy
albuminuria, however, have a poor value to predict the
subsequent development of preeclampsia [9].
(2) Kidney Function. The kidney is the organ most likely
to manifest endothelial injury related to preeclampsia.
Although the plasma creatinine concentration is generally
normal or only slightly elevated (1.0 to 1.5mg/dL (88 to
133mmol/L)), this could represent a decrease by 30–40% of
glomerularﬁltrationrate(GFR)forthevaluesexperiencedin
pregnant normotensive controls (Table 1). Renal failure is an
unusual complication that most often occurs in patients who
develop severe preeclampsia. Distinguishing preeclampsia
from an exacerbation of underlying renal disease can be
challenging. This is especially true in patients with preex-
isting proteinuria because protein excretion almost always
increases as pregnancy progresses. Preexisting renal disease
is a well-described risk factor for preeclampsia, and the onset
of preeclampsia in early pregnancy (before 32 weeks) is most
often seen in patients with underlying kidney disease or
hypertension.
(3)SerumUricAcid. Hyperuricemiawaspurportedlyamong
the earliest manifestation described in preeclampsia. Dif-
ferent theories were explored trying to explain this ﬁnding
[52]. In two systematic reviews published in 2006, serum
uric acid was found to be a poor predictor of preeclampsia
anditscomplications[53,54].Ameta-analysisbyKoopmans
et al. found uric acid to be useful to predict maternal
complications and assist with management of pre-eclampsia
[55]. First trimester elevated uric acid was associated with
later preeclampsia and more strongly with preeclampsia and
gestationalhypertensionwithhyperuricemiainaprospective
cohort study [56].
(4) Urinary Calcium Excretion. Hypocalciuria has been
reported in association with preeclampsia [57]. The mech-
anisms for this change is not clear, but multiple studies
designed to evaluate urinary calcium excretion have shown
that this parameter has no predictive value in the diagnosis
of preeclampsia [9].
7.3. Provocative Tests. Roll over test; isometric exercise test,
and angiotensin II sensitivity test [58–60]w e r ed e v i s e dt o
demonstrate the presence of abnormally increased vascular
activity during gestational weeks 28–32 and before the
clinical onset of preeclampsia. None of these tests are
currently being used clinically because they are expensive,
time-consuming, invasive, subjective, and, most important,
unreliable.
7.4. Doppler Ultrasonography of the Uterine Arteries. The
inadequateplacentalperfusionhasleadtotheuseofDoppler
ultrasonography to assess the velocity of the blood ﬂow in
the uterine arteries. A persistence of an early diastolic notch
after 24 weeks of gestation or abnormal ﬂow velocity ratio’s
has been associated with an inadequate trophoblast invasion.
Pregnancies associated with an abnormal uterine Doppler
after 24 weeks of gestation (high pulsatility index and/or
presence of an early diastolic notch) are associated with a
more than six-fold increase in the rate of preeclampsia [61].
Among high-risk patients with a previous preeclampsia,
Doppler ultrasound of the uterine arteries has an excellent
negative predictive value [62].
Current data do not support the use of Doppler ultra-
sonography for routine screening of patients for preeclamp-
sia [63]. However, several studies have shown that the
measurement of uterine perfusion in the second trimester
and analysis of angiogenic markers have a high detection rate
especially for early onset preeclampsia [64, 65].
7.5. Biomarkers in Prediction and Diagnosis of Preeclampsia.
Several markers heretofore described, might help, alone or in
combination to predict and/or diagnose preeclampsia. The
data, however, are derived largely from small case studies
in selected population. When evaluating new screening
strategies, not only sensitivity, speciﬁcity, and predictive
values need to be taken into account, but costs, patient’s
acceptability, and quality control also must be considered.
Studies have consistently reported elevated serum levels
ofsFlt-1inwomenwithpreeclampsiacomparedwithnormal
pregnancies [66–68]. Levine et al. reported a mean sFlt-1
value of 4382pg/mL in women with preeclampsia compared
with 1643pg/mL in the control group [66]. Similar values
have been reported in other studies [69–71], with most con-
cluding that the higher the sFlt-1 level, the more predictive it
is of preeclampsia. Importantly, this increase in serum sFlt-1
levels may be detected up to 5wks before the clinical onset of
clinical symptoms.
Levine et al. found a mean serum PGF concentration
in women with preeclampsia of 137pg/mL compared with
669pg/mL in controls [66]. Unfortunately, there was a
substantial overlap in the sFlt-1 and PGF concentrations
between patients destined to develop preeclampsia and those
who will go on to have normal pregnancies. Widmer et
al. also reported considerable diﬀerence in the methods of
various studies and concentrations of sFlt-1 in a systematic
review published in 2007 [72].
More recently, the assessment of the sFlt-1: PGF ratio
in the maternal serum has been proposed as more reliable
marker of overall preeclampsia risk. Preliminary data sug-
gests that this ratio may be more accurate than sFlt-1 or PGF
alone [70]. This test was launched in Europe by Roche as a
second trimester screening test for preeclampsia. A ﬁnancial
analysis found that the cost of this test when added to the
standard protocol was negated by timely management of
patients who would not have been diagnosed if only existing
tests had been used (false negative cases) [73].
Increased maternal serum levels of sEng were detected
prior to preeclampsia onset in healthy, nulliparous women
[74, 75] as well as in high-risk pregnant population [76].
A Korean study demonstrated that the combined ratio of
(sFlt-1 + soluble endoglin):(PGF + TGF beta −1) during
the second trimester had the highest odds ratio and lowest
false positive rate as compared to the individual markers for
prediction of preeclampsia [77].Journal of Pregnancy 9
The results of various studies, unfortunately, have been
inconsistent, and larger studies in more heterogenous pop-
ulation are needed to better deﬁne the clinical utility of
these tests. There is some data, however, to suggest that
tests for these biomarkers may be of use when applied to
selected high-risk patients such as those with underlying
hypertension [78].
The other suggested markers for the prediction or
detection of preeclampsia are
(i) placental protein 13 (PP-13);
(ii) pregnancy-associated plasma protein A (PAPP A);
(iii) inhibin A;
(iv) P-selectin;
(v) activin A;
(vi) pentraxin;
(vii) cell-free fetal DNA;
(viii) ADAM-12;
(ix) beta-HCG;
(x) 2-Methoxyestradiol (2-ME).
8. Consequences of HypertensioninPregnancy
Hypertension in pregnancy is a major cause of maternal
morbidity and mortality in the United States. There is
approximately one maternal death due to preeclampsia-
eclampsia per 100,000 live births, with a case-fatality rate
of 6.4 deaths per 10,000 cases [79, 80]. The outcome of
hypertension in pregnancy is, not surprisingly, aﬀected by
multiple factors. These embrace (but are not limited to)
gestational age at onset, severity of disease, and the presence
of comorbid conditions including diabetes mellitus, renal
disease, thrombophilia, or preexisting hypertension [81].
Adverse outcomes related to hypertension in pregnancy can
be divided into short-term versus long-term complications.
While short-term complications can be further subgrouped
into maternal and fetal complications, long-term outcomes
are mainly maternal.
8.1. Short-Term Complications
8.1.1. Maternal. Outcomes for pregnancy complicated by
hypertension range from uneventful pregnancy in women
with chronic, controlled hypertension to death in cases
of preeclampsia-eclampsia. The major adverse outcomes
include central nervous system (CNS) injuries such as
seizures (eclampsia), hemorrhagic and ischemic strokes,
hepatic damage ranging from transaminase elevation, the
so-called “HELLP syndrome” (hemolysis, elevated liver
enzymes, and low platelets), hepatic failure, renal dys-
function (spanning the gamut from a trivial reduction
in glomerular ﬁltration rate and minimal proteinuria to
reversible acute renal failure or so-called acute tubular
necrosis to even irreversible renal failure secondary to renal
cortical necrosis) as well as increased frequency of cesarean
delivery, preterm delivery, and abruptio placentae [2, 80, 81].
8.1.2. Fetal. The eﬀects of chronic, controlled hyperten-
sion in pregnancy on the fetus are minimal. However,
preeclampsia-eclampsia can lead to higher frequency of
induced labor, fetal growth restriction, neonatal respiratory
diﬃculties, and increased frequency admission to neonatal
intensive care unit. Hypertension in pregnancy, even in its
more severe forms, causes only minimal increased risk for
perinatal or fetal death [2, 82].
8.2. Long-Term Complications. Though hypertension in
pregnancy/preeclampsia is usually thought of as a short-
term problem that resolves itself with delivery, it still carries
signiﬁcant risk for remote complications. Those infants born
small and premature may experience prolonged stays in
neonatal intensive care units and often face developmental
delays. Remote outcomes include the risk of preeclampsia
in subsequent pregnancies and several long-term maternal
health risks as described below.
8.2.1. Risk of Recurrence. The risk of recurrent preeclampsia
in subsequent pregnancies varies with the severity and time
of onset of the acute episode [63]. It is estimated that women
with severe, early preeclampsia during their ﬁrst pregnancy
will have a high risk of recurrent preeclampsia in their
subsequent pregnancies (25–65%) [83, 84]. On the other
hand, for milder forms of preeclampsia the risk of recurrent
episode is still elevated, though to a lesser degree (5–7%)
in comparison to women who remained normal during
their ﬁrst pregnancy (1%) [85–87]. The recurrence risk of
preeclampsia is lower when the ﬁrst pregnancy was a twin as
compared to a singleton pregnancy [88].
8.2.2. Cardiovascular Complications. The association
between preeclampsia and cardiovascular diseases is both
well described and well documented. Women with history
of preeclampsia are at signiﬁcantly increased risk to develop
hypertension, ischemic heart disease, stroke, type II diabetes,
and venous thromboembolism in comparison with women
without history of the disease [89]. Factors linked to
increased risk of long-term cardiovascular diseases are
early onset preeclampsia, recurrent preeclampsia, severe
preeclampsia, gestational hypertension, or preeclampsia
with onset as a multipara [89]. Peripartum cardiomyopathy
more often develops in women with preeclampsia. The
pathophysiologic relation between preeclampsia and
subsequent late-developing cardiovascular disease is
unclear. Many hypotheses have been explored including
impaired endothelial function, increased insulin resistance,
sympathetic overactivity, proinﬂammatory activity, and the
abnormal lipid proﬁle, which usually constitute an early
manifestation of metabolic syndrome [90–94].
8.2.3. Renal Disease. More renal biopsies are undertaken in
victims of preeclampsia than in unaﬀected women [95].
There is also an increased risk for women with history of
preeclampsia to develop end-stage renal disease (ESRD),
though the absolute risk appears to be low. A recently
published study that evaluated data from the Norwegian10 Journal of Pregnancy
national birth and ESRD registries found that the risk
of subsequent ESRD increases with increased recurrent
episodes of preeclampsia in two or more pregnancies [95].
8.2.4. Cancer. Multiple observational studies evaluated the
possible association between hypertension in pregnancy
and cancer risk. Overall, women with preeclampsia were
found to be at reduced risk or had no excess risk of
cancer when followed by extended periods postpartum [96–
99]. This was conﬁrmed by a recent systematic review
that found no signiﬁcant association between preeclampsia
and risk of cancer. This “protective” eﬀect of preeclampsia
may be explained, at least in part, by the possible role of
the immune system in the disease pathogenesis. Women
with responsive immune systems may be more vulnerable
to develop preeclampsia but enjoy some protection from
malignancy.
9. Treatment of Hypertension
Theﬁrstprinciple oftreatmentofhypertensioninpregnancy
is to correctly diagnose the category (Table 1)a n ds e v e r i t yo f
thehypertension.Implicittothisguideistheaforementioned
limited value of attempting to completely normalize the
blood pressure in this setting. The second and perhaps even
more important principle is to understand the potential
vulnerability of the fetus to treatment.
9.1. Chronic Hypertension. The estimated prevalence of
chronichypertensioninpregnancyinUnitedstatesis3%and
hasbeenincreasingovertime.Thisincreaseinprevalencehas
been attributed to the increased prevalence of obesity and
delay in childbearing to ages, when chronic hypertension is
more common [100]. Although these patients are at higher
risk of superimposed preeclampsia, many will naturally
experience a physiological lowering of blood pressure during
pregnancy, and a reduction in the requirement for any
previously prescribed antihypertensive medication. A return
to blood pressure in hypertensive range in the third trimester
isnotunexpected.Thegoaloftreatmentistomaintainblood
pressureatalevelthatpreventsmaternalcerebrovascularand
cardiovascular complications. Prevention of preeclampsia is
desirable; however, current evidence has not shown that
eitherspeciﬁcbloodpressuretargetsinpregnancy,orspeciﬁc
antihypertensive agents modify the risk of superimposed
preeclampsia in women with preexisting hypertension [101].
Women with the following conditions are at increased
risk for maternal and fetal complications and should have a
lower threshold for treatment [102]:
(i) underlying renal disease;
(ii) secondary hypertension;
(iii) end-organ damage (e.g., ventricular dysfunction,
retinopathy);
(iv) maternal age over forty years old;
(v) microvascular disease;
(vi) history of stroke;
(vii) previous perinatal loss;
(viii) diabetes.
9.2. Gestational Hypertension. Gestational hypertension is
elevated blood pressure, which develops after 20 weeks
of gestation in a previously normotensive woman, though
without proteinuria. It complicates 6% of all pregnancies.
These women are at high risk for developing preeclampsia
that can occur at any time including the ﬁrst postpartum
week and need close monitoring. Approximately 15–45%
will eventually develop preeclampsia [103, 104]. The goal of
treatment is same as chronic hypertension.
9.3.Preeclampsia. Thegeneralprinciplesasoutlinedtoguide
the treatment of women with chronic hypertension are
applicable to the preeclamptic patients. Close monitoring to
recognize fetal distress while receiving treatment is essen-
tial. Early onset preeclampsia (less than thirty-four weeks)
requires careful use of antihypertensive medications, bed
rest, and in-hospital monitoring of both mother and fetus.
Thisapproachmayhelpdelaydeliveryandthusimprovefetal
outcome. Often these patients are intravascularly depleted
and are more susceptible to precipitous, drug-induced drops
in blood pressure. If signs of other fetal or maternal distress
are noted, delivery is the deﬁnitive treatment. Concerns
about hypotension and decreased uteroplacental blood ﬂow
are central to the treatment of the preeclamptic patient,
since placental ischemia is the focal point of preeclampsia
pathophysiology. Furthermore, lowering of BP does not
reverse the primary process. The ultimate goal of antihyper-
tensive therapy is to reduce the main risks to the mother,
which include placental abruption, accelerated hypertension
requiring hospitalization, and target organ-damage includ-
ing cerebrovascular and cardiovascular complications. One
must be cognizant of the risk for target organ damage is
increased, when a sudden change in blood pressure occurs
in previously normotensive women. As is true in all dynamic
clinical settings, individualization of care is often the rule.
In most instances, delivery of preeclamptics is indicated after
37 weeks of gestation or when fetal lung maturity has been
conﬁrmed.
9.4. Superimposed Preeclampsia. Superimposed preeclamp-
sia complicates approximately 25% of pregnancies in women
with chronic hypertension [102]. Principles of management
are the same as outlined earlier for preeclampsia, although
these women have more likelihood of developing severe
hypertension, requiring multiple antihypertensive medica-
tions.
10.Goalsof Treatment
10.1. Mild-to-Moderate Hypertension in Pregnancy. The ben-
eﬁts of antihypertensive therapy for mild to moderately
increased blood pressure in pregnancy (≤160/109mmHg),
either chronic or de novo, have not been shown in clinical
trials. A Cochrane meta-analysis concluded that there are
insuﬃcient data to determine the beneﬁts and risks ofJournal of Pregnancy 11
antihypertensive therapy for mild-to-moderate hypertension
(deﬁned as blood pressure 140–160mmHg systolic or
diastolicbloodpressure90–109mmHg)[101].Ofnote,with
antihypertensive treatment there seems to be less risk of
developing severe hypertension (relative risk, 0.50; with a
number needed to treat of 10) but no diﬀerence in outcomes
of preeclampsia, neonatal death, preterm birth, and small for
gestational age babies with treatment [101].
International guidelines for the treatment of hyperten-
sion in pregnancy vary with respect to thresholds for starting
treatment and targeted BP goals. Therapy is recommended
in the United states for a BP of 160/105mmHg or greater
[1] with no set treatment target; in Canada for women with
no comorbid conditions therapy is recommended for blood
pressureof140–150/90orgreater,targetingdiastolicpressure
to 80–90mmHg and in those with comorbid conditions
targeting 130–139/80–89mmHg [105, 106].
10.2. Severe Hypertension. There is consensus that treatment
is indicated for severe hypertension in pregnancy, deﬁned as
160/110mmHg or greater, to prevent intracerebral hemor-
rhage and maternal death [1, 107]. Those with hypertensive
encephalopathy,hemorrhage,oreclampsiarequiretreatment
with parenteral agents to lower mean arterial pressure (two-
thirds diastolic + one-third systolic blood pressure) by 25%
over minutes to hours, and then to further lower blood
pressure to 160/100mmHg over subsequent hours [1].
10.3. Severe Preeclampsia. Patient with severe preeclampsia
are managed diﬀerently as chances for maternal and fetal
complications are much higher. The criteria for diagnosis of
severe preeclampsia are outlined below:
(i) sustained systolic blood pressure ≥160mmof Hg;
(ii) sustaineddiastolicbloodpressureof ≥110mmofHg;
(iii) pulmonary edema;
(iv) oliguria <500mL/24 hours;
(v) persistent headaches or scotoma;
(vi) thrombocytopenia <100,000/mm3;
(vii) persistent right upper quadrant pain or epigastric
pain;
(viii) intrauterine growth restriction <10th percentile.
The ultimate treatment in severe preeclampsia is prompt
delivery. The timing of delivery is based on both maternal
and fetal indications. If gestational age is less than 34
weeks, expectant management, when possible should be
attempted with the aim of improving neonatal outcome
without compromising the safety of the mother. This
requires close inpatient monitoring of both mother and
the fetus. If possible, delivery should be 48 hours after
glucocorticoid administration to maximize fetal lung matu-
rity and improve neonatal outcome. Prior to delivery, the
focus is to improve placental perfusion by enhancing cardiac
output and peripheral vasodilatation. Patient should be
placed in lateral or supine position, which will optimize
venous return and cardiac output. These patients are often
intravascularly volume-depleted and require some degree of
perfusion. Magnesium sulfate seizure prophylaxis is typically
initiated in severe preeclamptics. The recommended dose for
magnesium sulfate is 4–6gm iv over 20 minutes followed
by continuous infusion at 2g/hr, which will maintain most
patient at therapeutic range of >4meq/mL. Blood pressure
management is same as outlined above for severe hyperten-
sion with target BP of 150/100. Rapid vasodilatation with
consequent hypotension should be obviated by adequate
intravascular resuscitation. An absolute fetal or maternal
indication for delivery requires immediate intervention.
Delivery can be induced with oxytocin and prostaglandin. If
induction fails, cesarean delivery is indicated.
11. Choice of AntihypertensiveDrugs
All antihypertensive drugs cross the placenta but to variable
degrees and most are agents categorized as “Category C.”
Therearenodatafromlargewell-designedrandomizedtrials
strong enough to mandate the use of one drug over another.
Diﬀerent drugs will be discussed separately based on their
pharmacological actions and summarized in Table 4 [108].
11.1. Sympathetic Nervous System Inhibitors
11.1.1. Centrally Acting Agents. Methyldopa is one of the
most widely used drugs for the treatment of hyperten-
sion in pregnancy. It is a prodrug metabolized to alpha
methylnorepinephrine, which then replaces norepinephrine
in the neurosecretory vesicles of adrenergic nerve terminals.
BP control is gradual, over six to eight hours, because of
the indirect mechanism of action. It is not thought to be
teratogenic based on limited data and forty-year clinical
experience. Treatment with methyldopa has been reported
to prevent subsequent progression to severe hypertension in
pregnancy[109]anddoesnotseemtohaveadverseeﬀectson
uteroplacental or fetal hemodynamics [110].
Adverse eﬀects are based on central alpha-2 blocking
eﬀect or decreased peripheral sympathetic tone. This drug
can cause decreased mental alertness and impaired sleep,
leading to sense of fatigue in some or depression in others.
Still other observed side eﬀects are decreased salivation,
leading to xerostomia (chronic dry mouth), elevated liver
enzymes in 5%; hepatitis and hepatic necrosis have also been
reported. Some patients will develop a positive antinuclear
antigen or antiglobulin (Coombs’) test with chronic use,
which may occasionally cause clinical hemolytic anemia.
Clonidine, a selective alpha-2 agonist, acts similarly and
is comparable to methyldopa with respect to safety and
eﬃcacy [111], but of some concern is a small controlled
follow-up study of twenty-two neonates that reported an
excess of sleep disturbance in clonidine-exposed infants
[112]. In pregnancy, it is mainly used as a third-line agent
for multidrug control of refractory hypertension.
11.1.2. Peripherally Acting Agents. B-blockers have been
extensively used in pregnancy. Concern still remains about
their safety in pregnancy based on data derived from a few12 Journal of Pregnancy
Table 4: Antihypertensives in pregnancy.
Drugs Method of action
(MOA) Side eﬀects Fetal concerns Indication Dosage
(I) Sympathetic nervous system inhibitors
(A) Central acting
(1) Methyldopa
agent of choice
Alpha2 agonist.
Onset is gradual
(6–8hrs)
Decreased
mental
alertness,
impaired sleep,
sense of fatigue
and depression,
xerostomia
Considered safe
(Category B)
Preferred
drug for non
emergent BP
control
0.5–3gm PO in 2
divided doses
(2) Clonidine Alpha-2 agonist As above
Limited data
(Category C).
Considered safe as
same MOA as
methyldopa
Nonemergent
BP control
to 0.3mg
q8–12hrs
(B) Peripheral acting
(1) Labetalol Beta and alpha
blocker
Fatigue,
lethargy,
exercise
intolerance,
sleep
disturbances,
and asthma
Concern for LBW
infants and
decrease
uteroplacental
blood ﬂow though
long-term data
suggesting safety.
Risk of neonatal
hypoglycemia at
higher doses
(Category C)
Nonemergent
and emergent
Bp control
20–1200mg in
2-3 divided doses.
10–20mg IV then
20–80mg IV
every 20–30
minutes,
maximum of
300mg: for
infusion
1-2mg/min
(II) Calcium channel blockers
(A) Nifedipine
Calcium channel
blocker
Dihydropyridine
Tachycardia,
palpitations,
peripheral
edema,
headache, and
facial ﬂushing
Does not cause
decrease maternal
blood ﬂow.
Concern regarding
concomitant uses
with magnesium
though not proven
in recent
evaluations
(Category C)
Non-
emergent and
emergent BP
control
30–120mg
extended release
preparations
(III) Direct vasodilators
(A) Hydralazine
Selectively relaxes
arteriolar smooth
muscle by an
unknown
mechanism
Acutely:
Headache,
nausea,
ﬂushing,
palpitations.
Chronic use:
Pyridoxine-
responsive
polyneuropathy
or immunologic
reaction like
drug induced
lupus
Eﬀect on
uteroplacental
blood ﬂow is
uncertain.
Associated with
more maternal and
perinatal adverse
events than other
agents when used
acutely. Neonatal
thrombocytopenia
and Lupus have
been reported. Not
proven to be
teratogenic
Useful in
combination
with sympa-
tholytic
agents. Used
for emergent
and
nonemergent
BP control
50–300 POmg in
2–4 divided
doses. 5mg IV,
then 5–10mg
every 20–40min:
once BP
controlled repeat
every 3 hours. For
infusion: 0.5 to
10mg/hrJournal of Pregnancy 13
Table 4: Continued.
Drugs Method of action
(MOA) Side eﬀects Fetal concerns Indication Dosage
(B) Sodium nitroprusside
Relatively contraindicated.
Considered as a last resort
Direct NO
inhibitor
Non-selectively
relaxes arteriolar
and venular
vascular smooth
muscles
Excessive
vasodilation and
cardioneuro-
genic syncope in
volume depleted
patients.
Cyanide toxicity
if used greater
than 4 hours.
Labor arrest
hyperglycemia
Risk of fetal
cyanide
intoxication
remains unknown
Only for
emergent Bp
control as last
resort
30–50mg IV
every 5–15
minutes Infusion
at 0.25–
5.0mcg/kg/min
(IV) Diuretics
(A) Hydrochlorothiazide
Thiazide
diuretics. Blocks
Na channels in
distal-convoluted
tubules
Volume
contraction and
electrolyte
disturbances.
Hyperuricemia
Volume
contraction may
limit fetal growth,
though not proven
in studies
Nonemergent
BP control 12.5–25mg/day
(V) ACE-I and ARB
Contraindicated in pregnancy.
Should be discontinued prior to
conception
ACE-I: inhibits
angiotensin-
converting
enzyme
interfering with
conversion of
angiotensin I to
angiotensin II
ARB: antagonizes
ATI receptor
Angioedema,
hypotension,
hyperkalemia,
renal failure.
Cough (only in
ACE-I)
ACE-I: renal
dysgenesis,
oligohydramnios,
calvarial and
pulmonary
hypoplasia, IUGR.
Neonatal anuric
renal failure, fetal
death Arbs: same
concerns
Not indicated N/A
small studies, which suggests an association with low birth
weight infants. Atenolol, for example, in one such study
started at twelve to twenty-four weeks’ gestation, resulted in
clinically signiﬁcant fetal growth restriction and decreased
placental weight compared with placebo [113, 114]. None of
the b-blockers have been associated with teratogenicity. Oral
agents have been associated with nonclinically signiﬁcant
neonatal bradycardia. Parenteral therapy has been found
to increase the risk of neonatal bradycardia in one of six
newborns. Results from one-year follow-up study, which
showed normal development of infants exposed to atenolol
in utero, are reassuring [115]. In a recent Cochrane analysis,
b-blockers were found to be more eﬀective in lowering BP
than methyldopa in ten trials.
Labetolol, a nonselective beta- and alpha-blocker has
gained wide acceptance in pregnancy. Oral administration
is considered safe and eﬀective as methyldopa [116, 117],
although neonatal hypoglycemia is reported at high doses.
Based on one placebo trial, it has been associated with
growth restriction when used in management of preeclamp-
sia remote from term. Parenterally it is used to treat
severe hypertension, and because of a lower incidence of
maternal hypotension and other side eﬀects, many ﬁnd this
drug preferable to hydralazine. Reported adverse events are
fatigue, lethargy, exercise intolerance, peripheral vasocon-
striction, sleep disturbance, and bronchoconstriction. It has
moved up to the category of a ﬁrst-line agent in the opinion
of many clinicians.
Peripherally acting alpha-adrenergic antagonists are
second-line antihypertensive drugs in nonpregnant adults.
These are indicated during pregnancy in the management
of hypertension in patients suspected to have pheochromo-
cytoma. Both prazosin and phenoxybenzamine have been
used, with b-blockers used as adjunctive agents after alpha-
blockade is accomplished [118, 119]. There is only limited
experience with these agents in pregnancy; therefore, their
routine use cannot be advocated.
11.2. Calcium Channel Blockers. These drugs have been used
to manage chronic hypertension, mild pre-eclampsia pre-
senting late in gestation and urgent hypertension associated
with preeclampsia. Both nifedipine a nondihydropyridine
calcium channel blocker and verapamil are not associated
withteratogenicriskstofetusexposedinﬁrsttrimester[120].
Maternal adverse eﬀects with nifedipine include tachycardia,
palpitations, peripheral edema, headaches, and facial ﬂush-
ing. Nifedipine does not seem to cause a detectable decrease
in uterine blood ﬂow [121, 122]. Short-acting dihydropy-
ridine calcium antagonists, particularly when administered14 Journal of Pregnancy
sublingually, are now not recommended for the treatment
of hypertension in nonpregnant patients because of reports
of myocardial infarction and death in hypertensive patients
with coronary artery disease. In pregnant patients, these
formulations are associated with maternal hypotension and
fetal distress [123, 124] and are generally not recommended.
In contrast long-acting oral nifedipine in pregnant patients
with severe hypertension in pregnancy has been shown to
be safe and eﬀective [125]. Dihydropyridine compounds also
have a tocolytic eﬀect and can delay the onset or slow the
progression of labor. Nondihydropyridine agents such as
verapamil and diltiazem may have added value in women
with proteinuria because of their antiproteinuric action.
A concern with the use of calcium antagonists for BP
control in preeclampsia has been the concomitant use of
magnesium sulfate to prevent seizures. Drug interactions
between nifedipine and magnesium sulfate were reported to
causeneuromuscularblockade, myocardial depression, or, in
some cases, circulatory collapse. Despite this concern, recent
evaluation showed that these medications are commonly
used together without increased risk.
11.3. Diuretics. Diuretics are ﬁrst-line agents to be used in
management of essential hypertension prior to conception
and, based on their apparent safety, they may be continued
during pregnancy alone or in combination with other agents
especially in women more likely to have salt-responsive
hypertension [1]. Concerns regarding volume contraction
leading to limited fetal growth have not been supported
in studies [126]. Mild volume contraction, however, may
lead to hyperuricemia and in doing so invalidate serum uric
acid levels as a laboratory marker that may assist in the
diagnosis of superimposed preeclampsia. The adverse eﬀects
are mainly due to ﬂuid, electrolytes, and solute disturbances.
In women already taking, hydrochlorothiazide may be
continuedduringpregnancy;useoflow-doses(12.5to25mg
daily) may minimize untoward metabolic eﬀects, such as
impaired glucose tolerance and hypokalemia [127]. The
potassium sparing diuretics triamterene and amiloride do
not appear to be teratogenic based on a small numbers of
case reports [127]. On the other hand, spironolactone is not
recommended because of its antiandrogenic eﬀects during
fetal development, noted in animal models, although this
concern was not borne out in an isolated clinical case, where
this agent was employed [128].
11.4. Direct Vasodilators. Hydralazine: selectively relaxes
arteriolar smooth muscle by an as yet unknown mechanism.
The most important indication is severe hypertension or a
third-line agent in control of refractory hypertension. It can
be used orally, intravenously, or intramuscularly. Adverse
eﬀects are due to excessive vasodilation or sympathetic
activation (headache, nausea, ﬂushing, or palpitations).
Chronic use can lead to (in rare cases) a pyridoxine-
responsive polyneuropathy or to immunologic reactions,
including a drug-induced lupus syndrome. Hydralazine has
been used in all trimesters of pregnancy, and data have
not shown an association with teratogenicity, although
neonatal thrombocytopenia and lupus have been reported
[129]. For acute severe hypertension later in pregnancy,
intravenous hydralazine has been associated with more
maternal and perinatal adverse eﬀects than intravenous
labetalol or oral nifedipine. Maternal hypotension, cesarean
sections, placental abruptions, Apgar scores less than 7,
and oliguria occur more frequently following hydralazine. A
recent meta-analysis of the use of intravenous hydralazine in
severe hypertension in pregnancy concluded that parenteral
labetalol or oral nifedipine were preferable ﬁrst-line agents,
with hydralazine as a suitable second-line agent [130].
11.4.1. Isosorbide Dinitrates. this agent has been investigated
in a small study of gestational hypertensive and preeclamptic
pregnant patients. It was found that cerebral perfusion pres-
sure is unaltered by isosorbide dinitrate, despite signiﬁcant
changes in maternal BP, thus decreasing the risk for ischemia
and infarction, when BP is lowered [131].
11.4.2. Sodium Nitroprusside. This direct nitric oxide donor,
which relaxes both arteriolar and venular vascular smooth
muscles. It is used only as continuous infusion and is
easily titrated because of its near immediate action of
onset and only three-minute duration of action. Nitroprus-
side metabolism releases cyanide, which can reach toxic
levels when infused rapidly. Cyanide metabolizes to thio-
cyanate which can lead to toxicity in 24–48 hours. Adverse
eﬀects include excessive vasodilation and cardioneurogenic
(i.e., paradoxical bradycardia) syncope in volume-depleted
preeclamptic women [132].
N.B.: The risk of fetal cyanide intoxication remains
unknown. Given the long experience with hydralazine and
alternativeuseofparenterallabetalolororalcalciumchannel
blockers, this drug is considered as a last resort.
11.5. Serotonin Receptor Blockers. Serotonin-induced vasodi-
lation is mediated by S1 receptors and subsequent release of
prostacyclin and NO. Ketanserin is a selective S2 receptor-
blocking agent that has been used in the nonpregnant
population. Based on the data available from Australia and
South Africa, it may be safe to use in pregnancy and
useful in treatment of chronic hypertension in pregnancy,
preeclampsia,andHELLPsyndrome[133,134].FDAhasnot
approved Ketanserin for use in United States.
11.6. Angiotensin-Converting Enzyme Inhibitors (ACE-I) and
Angiotensin Receptor Antagonists (ARB). ACE-I and ARB are
contraindicated in 2nd and 3rd trimesters because of severe
toxicity secondary to reduced renal perfusion of the fetal
kidneys. Their use has been associated with renal dysgenesis,
oligohydramnios as a result of fetal oliguria, calvarial and
pulmonary hypoplasia, intrauterine growth restriction, and
neonatal anuric renal failure, leading to death of the fetus
[135, 136]. ARBs have also been associated with fetal demise
and same concerns are applicable to the use of direct
renin inhibitors. First trimester exposure to these agents
has been associated with greater incidence of cardiovascular
and central nervous system malformations. Whether theseJournal of Pregnancy 15
eﬀects are secondary to hemodynamic eﬀects or speciﬁc
requirement of angiotensin II as a fetal growth factor is
unknown. Patients should, therefore, be counseled to stop
these medications while attempting to conceive. The risk
of birth defects increased from 3 to 7% while on these
medications at the time of conception [137].
12. PostpartumHypertension
Some women experience a rise in their BP in the postpartum
period, which typically reaches a maximum on the ﬁfth
postpartum day. This has been attributed to volume expan-
sion and ﬂuid mobilization in postpartum period. The time
period, beyond which patients with gestational hypertension
and preeclampsia are labeled chronic hypertensive, is not
well deﬁned. The threshold for treatment in these patients
has not been uniformly established, but medication is
generally recommended to be started when systolic BP
exceeds 150mmHg or diastolic BP is greater than 100mm
of Hg [138] .T h ec h o i c eo fa n t i h y p e r t e n s i v ea g e n t si s ,o f
course, inﬂuenced by whether or not the patient is breast-
fed. In selected patients with severe preeclampsia, especially
those with hypertension accompanied by peripheral and
pulmonary edema, a short course of loop diuretics may be
beneﬁcial.
NSAIDS may contribute to postpartum hypertension as
per few case reports [139], and thus their use should be
avoided in patients who are already hypertensive.
13.BreastFeeding
Neonatal exposure to methyldopa via nursing is likely low
and is generally considered safe. Atenolol and metoprolol
are concentrated in breast milk, possibly to levels that could
aﬀect the infant; by contrast, exposure to labetolol and
propanololappearslow[140].Althoughmilkconcentrations
of diuretics are low and considered safe, these agents, by
inducing volume contraction in mother, can decrease milk
production [141]. There are reports of calcium channel
blockers transfer into breast milk [142], but the relative
infant dose of nifedipine, verapamil, and diltiazem is low,
and all are safe during breast-feeding. Suﬃcient data exist
for the safety of three ACE inhibitors: captopril, enalapril,
and quinapril; these drugs are deemed to be compatible
with breast-feeding by the American Academy of Pediatrics
[143]. There are currently insuﬃcient data on angiotensin II
receptorblockers andatthistime therecommendationis not
to use these drugs during breast-feeding.
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